Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids

References

• Stewart E, USA MCDoREaIRM, Cookson C, et al. Epidemiology of uterine fibroids: a systematic review. BJOG Int J Obstetrics Gynaecol. 2017;124(10):1501–1512.
   PubMed Web of Science ®Google Scholar
• Cramer SF, Horiszny JA, Leppert P. Epidemiology of uterine leiomyomas. With an etiologic hypothesis. J Reprod Med. 1995 Aug;40(8):595–600.
   PubMed Web of Science ®Google Scholar
• Buttram VC Jr., Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981 Oct;36(4):433–445.
   PubMed Web of Science ®Google Scholar
• The Practice Committee of the American Society for Reproductive Medicine. American Society for Reproductive Medicine, Birmingham, Alabama. Myomas and reproductive function. Fertil Steril. 2008 Nov;90(5Suppl):S125–S130. Available from: http://dx.doi.org/10.1016/j.fertnstert.2008.09.012
   PubMedGoogle Scholar
• Fuldeore M, Yang H, Soliman AM, et al. Healthcare utilization and costs among women diagnosed with uterine fibroids: a longitudinal evaluation for 5 years pre- and post-diagnosis. Curr Med Res Opin. 2015;31(9):1719–1731.
   PubMed Web of Science ®Google Scholar
• Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 1992 Feb;166(2):746–751.
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011 Nov;96(5):1175–1189.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Meng CX. Emergency contraception: potential role of ulipristal acetate. Int J Womens Health. 2010 Aug;09(2):53–61.
   Google Scholar
• Seitz C, Bumbuliene Z, Costa AR, et al. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemp Clin Trials. 2017;55:56–62.
   PubMed Web of Science ®Google Scholar
• Schutt B, Kaiser A, Schultze-Mosgau MH, et al. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod. 2016 Aug;31(8):1703–1712.
   PubMed Web of Science ®Google Scholar
• Wagenfeld A, Bone W, Schwede W, et al. BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013 Aug;28(8):2253–2264.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012 Feb 2;366(5):421–432.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012 Feb 2;366(5):409–420.
   PubMed Web of Science ®Google Scholar
• Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014 Jun;101(6):1565–73 e1-18.
   Web of Science ®Google Scholar
• Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015 Feb;103(2):519–27 e3.
   PubMed Web of Science ®Google Scholar
• Parker WH. Uterine myomas: management. Fertil Steril. 2007 Aug;88(2):255–271.
   PubMed Web of Science ®Google Scholar
• Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: abdominal myomectomy and hysterectomy. Clin Obstet Gynecol. 2001 Jun;44(2):385–400.
   PubMed Web of Science ®Google Scholar
• Bhave Chittawar P, Franik S, Pouwer AW, et al. Minimally invasive surgical techniques versus open myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2014 Oct;21(10):Cd004638.
   Google Scholar
• Filipowska J, Lozinski T. Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MR-HIFU) in treatment of symptomatic uterine myomas. Pol J Radiol. 2014;79:439–443.
   PubMedGoogle Scholar
• Marshburn PB, Matthews ML, Hurst BS. Uterine artery embolization as a treatment option for uterine myomas. Obstet Gynecol Clin North Am. 2006 Mar;33(1):125–144.
   PubMed Web of Science ®Google Scholar
• Czuczwar P, Stepniak A, Wrona W, et al. The influence of uterine artery embolisation on ovarian reserve, fertility, and pregnancy outcomes - a review of literature. Przeglad Menopauzalny = Menopause Rev. 2016 Dec;15(4):205–209.
   PubMed Web of Science ®Google Scholar
• Hoellen F, Griesinger G, Bohlmann MK. Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opin Pharmacother. 2013 Oct;14(15):2079–2085.
   PubMed Web of Science ®Google Scholar
• Walker LM, Tran S, Robinson JW. Luteinizing hormone–releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer. 2013 Dec;11(4):375–384.
   PubMed Web of Science ®Google Scholar
• Bianchi S, Fedele L. The GnRH agonists in the treatment of uterine leiomyomas. Acta Eur Fertil. 1989 Jan–Feb;20(1):5–10.
   PubMedGoogle Scholar
• Moroni RM, Martins WP, Ferriani RA, et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev. 2015 Mar;20(3):CD010854.
   Google Scholar
• Moroni RM, Martins WP, Dias SV, et al. Combined oral contraceptive for treatment of women with uterine fibroids and abnormal uterine bleeding: a systematic review. Gynecol Obstet Invest. 2015;79(3):145–152.
   PubMed Web of Science ®Google Scholar
• Melis GB, Piras B, Marotto MF, et al. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):901–908.
   PubMed Web of Science ®Google Scholar
• Orihuela PA. Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids. Curr Opin Investig Drugs. 2007 Oct;8(10):859–866.
   PubMedGoogle Scholar
• Puchar A, Luton D, Koskas M. Ulipristal acetate for uterine fibroid-related symptoms. Drugs Today (Barc). 2015 Nov;51(11):661–667.
   PubMed Web of Science ®Google Scholar
• Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand. 1985;64(4):307–309.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013 Feb;34(1):130–162.
   PubMed Web of Science ®Google Scholar
• Patel B, Elguero S, Thakore S, et al. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015 Mar-Apr;21(2):155–173.
   PubMed Web of Science ®Google Scholar
• Maruo T, Ohara N, Yoshida S, et al. Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas. Expert Opin Drug Discov. 2011 Sep;6(9):897–911.
   PubMed Web of Science ®Google Scholar
• Xu Q, Takekida S, Ohara N, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5ʹ-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab. 2005 Feb;90(2):953–961.
   PubMed Web of Science ®Google Scholar
• Xu Q, Ohara N, Chen W, et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod. 2006 Sep;21(9):2408–2416.
   PubMed Web of Science ®Google Scholar
• Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008 Mar;14(3):181–191.
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005 May–Jun;11(3):293–307.
   PubMed Web of Science ®Google Scholar
• Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009 Aug;21(4):318–324.
   PubMed Web of Science ®Google Scholar
• Pohl O, Zobrist RH, Gotteland JP. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015 Apr;22(4):476–483.
   PubMed Web of Science ®Google Scholar
• Esmya 5 mg Tablets (ulipristal acetate) - Summary of product characteristics (SPC) - (eMC). 2016 Available from: https://www.medicines.org.uk/emc/medicine/26068
   Google Scholar
• Blithe DL, Nieman LK, Blye RP, et al. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003 Nov;68(10–13):1013–1017.
   PubMed Web of Science ®Google Scholar
• Larner JM, Reel JR, Blye RP. Circulating concentrations of the antiprogestins CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration. Hum Reprod. 2000 May;15(5):1100–1106.
   PubMed Web of Science ®Google Scholar
• Tafi E, Scala C, Leone Roberti Maggiore U, et al. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. Expert Opin Drug Saf. 2015 Jun;14(6):965–977.
   PubMed Web of Science ®Google Scholar
• Pohl O, Kendrick J, Gotteland JP. Metabolic disposition of [14C] ulipristal acetate in healthy premenopausal women. J Bioequiv Availab. 2013;5:177–184.
   Google Scholar
• Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 2008 May;111(5):1129–1136.
   PubMed Web of Science ®Google Scholar
• Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 2011 Feb;95(2):767–72 e1-2.
   Web of Science ®Google Scholar
• Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990 Aug;97(8):734–739.
   PubMedGoogle Scholar
• Fernandez H, Schmidt T, Powell M, et al. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results. Eur J Obstet Gynecol Reprod Biol. 2017 Jan;208:91–96.
   PubMed Web of Science ®Google Scholar
• Simon J, Catherino WH, Segars J, et al. First US-based phase 3 study of ulipristal acetate (UPA) for symptomatic uterine fibroids (UF): results of VENUS-I. Fertil Steril. 2016;106(3):e376.
   Google Scholar
• Simon JA, Catherino W, Blakesley R, et al. Ulipristal acetate treatment of uterine fibroids in black and obese women: venus I subgroup analyses [28G]. Obstetrics Gynecol. 2017;129:78S–79S.
   Web of Science ®Google Scholar
• Liu J, Soper D, Lukes AS, et al. VENUS II: the second us-based phase 3 study of ulipristal acetate (UPA) for treatment of symptomatic uterine fibroids (UF). Fertil Steril. 2017;108(3):e27–e28
   Web of Science ®Google Scholar
• De Milliano I, Van Hattum D, Ket JCF, et al. Endometrial changes during ulipristal acetate use: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2017 Jul;214:56–64.
   PubMed Web of Science ®Google Scholar
• Fauser BC, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One. 2017;12(3):e0173523.
   PubMed Web of Science ®Google Scholar
• Modaffari P, D’Alonzo M, Garbagnati M, et al. Unexpected uterine leiomyosarcoma in a woman with multiple myomas treated with ulipristal acetate: case report and literature review. Gynecol Endocrinol. 2017 Sep;21:1–3.
   Google Scholar
• Kadhel P, Smail M, Borja De Mozota D. Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma. J Gynecol Obstet Hum Reprod. 2017 Jun 21;46(7):609–611.
   PubMedGoogle Scholar
• Istre O. Unexpected uterine leiomyosarcoma during laparoscopic hysterectomy treated 6 months with ulipristal acetate and contained power morcellation. J Minim Invasive Gynecol. 2017 Feb;24(2):198.
   PubMed Web of Science ®Google Scholar
• Pohl O, Osterloh I, Gotteland JP. Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. J Clin Pharm Ther. 2013 Dec;38(6):512–517.
   PubMed Web of Science ®Google Scholar
• Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013 Jan;51(1):26–33.
   PubMed Web of Science ®Google Scholar
• Agency EM. Summary of opinion (initial authorisation) Esmya - Ulipristal acetate. Committee for Medicinal Products for Human Use (CHMP); 2011. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002310.jsp&mid=WC0b01ac058004d5c1
   Google Scholar
• Agency EM. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015. News and Events; 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002310.jsp&mid=WC0b01ac058004d5c1
   Google Scholar
• Ferrero S, Racca A, Tafi E, et al. 3-month versus 6-month treatment with ulipristal acetate prior to laparoscopic hysterectomy of large myomatous uteri. J Minim Invasive Gynecol. 2015 Nov–Dec;22(6S):S108.
   PubMedGoogle Scholar
• Bizzarri N, Ghirardi V, Remorgida V, et al. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. Eur J Obstet Gynecol Reprod Biol. 2015 Sep;192:22–26.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Racca A, Tafi E, et al. Ulipristal acetate before high complexity hysteroscopic myomectomy: a retrospective comparative study. J Minim Invasive Gynecol. 2016 Mar–Apr;23(3):390–395.
   PubMed Web of Science ®Google Scholar
• Wu TI, Yen TC, Lai CH. Clinical presentation and diagnosis of uterine sarcoma, including imaging. Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):681–689.
   PubMed Web of Science ®Google Scholar